Equities research analysts expect Omnicell, Inc. (NASDAQ:OMCL) to announce earnings per share (EPS) of $0.40 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Omnicell’s earnings, with the highest EPS estimate coming in at $0.41 and the lowest estimate coming in at $0.38. Omnicell posted earnings per share of $0.31 during the same quarter last year, which indicates a positive year over year growth rate of 29%. The firm is scheduled to issue its next earnings results on Thursday, July 26th.
According to Zacks, analysts expect that Omnicell will report full-year earnings of $1.97 per share for the current financial year, with EPS estimates ranging from $1.94 to $2.00. For the next fiscal year, analysts expect that the firm will report earnings of $2.36 per share, with EPS estimates ranging from $2.21 to $2.49. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Omnicell.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, April 26th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.04. Omnicell had a net margin of 4.55% and a return on equity of 4.11%. The firm had revenue of $182.60 million for the quarter, compared to analyst estimates of $177.49 million. During the same quarter last year, the business earned $0.06 earnings per share. Omnicell’s revenue was up 22.9% compared to the same quarter last year.
A number of analysts recently issued reports on the stock. Benchmark assumed coverage on shares of Omnicell in a research report on Friday. They set a “buy” rating and a $63.00 target price on the stock. ValuEngine upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Wednesday, June 20th. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 20th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $63.00 price target on shares of Omnicell in a report on Tuesday, April 3rd. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Omnicell currently has a consensus rating of “Buy” and an average target price of $56.00.
In other Omnicell news, insider Peter J. Kuipers sold 724 shares of Omnicell stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $46.00, for a total value of $33,304.00. Following the transaction, the insider now owns 56,970 shares in the company, valued at approximately $2,620,620. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Robin Gene Seim sold 15,658 shares of Omnicell stock in a transaction on Monday, June 4th. The shares were sold at an average price of $48.00, for a total transaction of $751,584.00. Following the completion of the transaction, the insider now owns 74,121 shares in the company, valued at approximately $3,557,808. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,755 shares of company stock worth $2,840,350. 3.71% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the company. California Public Employees Retirement System raised its stake in shares of Omnicell by 1.6% in the 4th quarter. California Public Employees Retirement System now owns 87,628 shares of the company’s stock valued at $4,250,000 after acquiring an additional 1,388 shares during the period. Kennedy Capital Management Inc. raised its stake in shares of Omnicell by 199.2% in the 4th quarter. Kennedy Capital Management Inc. now owns 465,483 shares of the company’s stock valued at $22,576,000 after acquiring an additional 309,913 shares during the period. Swiss National Bank raised its stake in shares of Omnicell by 2.6% in the 4th quarter. Swiss National Bank now owns 63,800 shares of the company’s stock valued at $3,094,000 after acquiring an additional 1,600 shares during the period. Rhumbline Advisers raised its stake in shares of Omnicell by 16.6% in the 4th quarter. Rhumbline Advisers now owns 88,153 shares of the company’s stock valued at $4,275,000 after acquiring an additional 12,543 shares during the period. Finally, First Trust Advisors LP purchased a new position in shares of Omnicell in the 4th quarter valued at $2,160,000. 98.79% of the stock is currently owned by institutional investors and hedge funds.
Shares of Omnicell opened at $52.45 on Monday, according to Marketbeat. Omnicell has a 1 year low of $39.75 and a 1 year high of $55.40. The company has a market cap of $2.04 billion, a P/E ratio of 99.25, a PEG ratio of 2.42 and a beta of 0.78. The company has a current ratio of 1.68, a quick ratio of 1.22 and a debt-to-equity ratio of 0.33.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.